{
  "summary": {
    "total_drug_approvals": 71203,
    "date_range": {
      "start": 1939,
      "end": 2024
    },
    "cluster_count": 2,
    "most_innovative_decade": {
      "decade": 1980,
      "decade_label": "1980s",
      "approval_count": 15987
    }
  },
  "clusters": [
    {
      "start_year": 1978,
      "end_year": 1987,
      "duration_years": 10,
      "years": [
        1978,
        1979,
        1980,
        1981,
        1982,
        1983,
        1984,
        1985,
        1986,
        1987
      ],
      "total_innovations": 16104,
      "avg_per_year": 1610.4,
      "peak_year": 1981,
      "peak_count": 1835,
      "therapeutic_breakdown": [
        {
          "area": "Corticosteroid [EPC]",
          "count": 228,
          "percentage": 18.3
        },
        {
          "area": "Benzodiazepine [EPC]",
          "count": 79,
          "percentage": 6.3
        },
        {
          "area": "Osmotic Diuretic [EPC]",
          "count": 70,
          "percentage": 5.6
        },
        {
          "area": "Nonsteroidal Anti-inflammatory Drug [EPC]",
          "count": 44,
          "percentage": 3.5
        },
        {
          "area": "Lipid Emulsion [EPC]",
          "count": 34,
          "percentage": 2.7
        }
      ],
      "top_sponsors": [
        {
          "name": "BAXTER HLTHCARE",
          "approvals": 1208
        },
        {
          "name": "OTSUKA ICU MEDCL",
          "approvals": 1133
        },
        {
          "name": "HOSPIRA",
          "approvals": 690
        },
        {
          "name": "B BRAUN",
          "approvals": 571
        },
        {
          "name": "WATSON LABS",
          "approvals": 530
        }
      ]
    },
    {
      "start_year": 1998,
      "end_year": 2002,
      "duration_years": 5,
      "years": [
        1998,
        1999,
        2000,
        2001,
        2002
      ],
      "total_innovations": 7727,
      "avg_per_year": 1545.4,
      "peak_year": 2002,
      "peak_count": 1621,
      "therapeutic_breakdown": [
        {
          "area": "Nonsteroidal Anti-inflammatory Drug [EPC]",
          "count": 99,
          "percentage": 6.8
        },
        {
          "area": "Corticosteroid [EPC]",
          "count": 86,
          "percentage": 5.9
        },
        {
          "area": "Benzodiazepine [EPC]",
          "count": 85,
          "percentage": 5.9
        },
        {
          "area": "Azole Antifungal [EPC]",
          "count": 41,
          "percentage": 2.8
        },
        {
          "area": "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]",
          "count": 39,
          "percentage": 2.7
        }
      ],
      "top_sponsors": [
        {
          "name": "WATSON LABS",
          "approvals": 290
        },
        {
          "name": "HOSPIRA",
          "approvals": 259
        },
        {
          "name": "SANDOZ",
          "approvals": 238
        },
        {
          "name": "NOVARTIS",
          "approvals": 219
        },
        {
          "name": "TEVA",
          "approvals": 214
        }
      ]
    }
  ],
  "metadata": {
    "analysis_date": "2025-11-11T20:20:47.731258",
    "clustering_threshold_sigma": 1.0,
    "min_cluster_size": 3,
    "drug_type_filter": "all",
    "total_records_analyzed": 71203
  }
}